EAU 2013 - Programme Book - YouMed

Sponsored Sessions
Sunday, 17 March
416 Programme Book
Sponsored Session
17.45 - 19.15 Silodosin: A first choice for the pharmacological treatment of BPH
Brown Hall 1-2 - Level S2
Symposium
Chair: F. Montorsi, Milan (IT)
Opening remarks
F. Montorsi, Milan (IT)
BPH: Where we are today
F.C. Hamdy, Oxford (GB)
Which patient and why - An analysis of pooled data from the phase III studies in EU and US
H. Lepor, New York (US)
G. Novara, Padova (IT)
The ‘real life’ profile of the BPH patient
H. Botto, Suresnes (FR)
Clinical cases and discussion
F. Montorsi, Milan (IT)
Concluding remarks
F. Montorsi, Milan (IT)
Aims and objectives
This symposium will discuss the potential role of silodosin, a highly selective alpha 1a-antagonist,
with reference to its usefulness as a first line pharmacological treatment of BPH.
This innovative and interactive programme will include a review of the latest pooled data analysis from
studies across the EU and US, highlighting the efficacy and safety of silodosin in a large patient population
and in particular subpopulations.
It will look at the ‘real life profile’ of a patient with BPH with a presentation emphasizing the appropriate
clinical management of patients presenting with symptoms of LUTS/BPH. The faculty will also present
interactive clinical cases and the audience will be encouraged to participate in the discussions around
appropriate management of these patients.
Sponsored by RECORDATI